IPF Treatment: Exploring Novel Approaches for Disease Modification
- Leveraging gene and RNA-based therapies to address underlying disease drivers beyond traditional antifibrotics
- Advancing innovative delivery systems to enhance lungspecific targeting while ensuring patient safety
- Assessing the current landscape of gene and RNA therapies in IPF and the path to regulatory and clinical success